Abstract:Abstract [Purpose] We synthesized polyethyleneglycol-lipid with different double arms (DDA-PEG) as the novel modification material on liposomal membrane, and reported that doxorubicin (DOX) contained DDA-PEG modified liposome (DDA-LDOX) had superior properties (cytotoxicity and DOX uptake into tumor cells). On the other hand, it was suggested that fixed aqueous layer thickness (FALT) around the liposomal membrane was concerned with long circulation in blood or antitumor effect. In 100th AACR meeting (2009), we reported the connection with the FALT and the biological factor (amount of DOX uptake / IC50 of cell cytotoxicity) in vitro. In this study, DDA-LDOX had been studied the antitumor activity on primary tumor in vivo. Moreover, another activity of DDA-LDOX was examined against liver metastasis as the risk factor in cancer therapy. [Methods] Liposome (DSPC/cholesterol/DSPG/PEG/DOX = 100:100:60:15:18 μmol) was prepared according to the method of Bangham. PEG2000 modified liposome and PEG2000/PEG500 modified liposome was expressed as Single-LDOX and Mixed-LDOX, respectively. Zeta potentials of liposomes were measured by the change of NaCl concentration in buffer and FALT was calculated. In the study of antitumor activity to primary tumor, M5076 ovarian sarcoma cells were transplanted into the backs of mice, and each liposomes were injected intravenously at a dose of 2.5 mg/kg on 19th, 22nd and 25th day after tumor inoculation. The mice were sacrificed after 48 hr from last administration, and the tumor was removed and weighed. In the study of anti-metastasis activity, M5076 ovarian sarcoma cells were inoculated in tail vein of mice. These mice were injected various liposomes at a dose of 2.5 mg/kg (i.v.) on 6th, 9th and 12th day after tumor inoculation. After 48 hr from last administration, the liver was removed and weighed, and score of liver metastasis was recorded (0-5 stage, 0: non-metastasis). [Results and discussion] In the result of antitumor activity, the tumor weight after Single-LDOX treatment was reduced to 65.5% of control level (1.13±0.45 g). In contrast, after DDA-LDOX treatment, it was reduced to 36.4% of control level. In anti-metastasis activity, the score of hepatic metastasis was DOX sol > plain-LDOX > Single-LDOX = DDA-LDOX. The inhibitory effect on liver metastasis by Single-LDOX and DDA-LDOX were obviously. The metastasis score correlated with the liver weight, namely, inhibition of metastasis by DDA-LDOX was supported from liver weight. DOX concentration in the liver was plain-LDOX > Single-LDOX = DDA-LDOX > DOX sol. Thus, we speculated that weak effect of plain-LDOX was caused by DOX accumulation into hepatic normal cell. In this study, the character of Single-LDOX was similar to DOXIL®, namely, it was suggested that DDA-LDOX increase the therapeutic efficacy, compared with DOXIL®. In conclusion, we expected that DDA-LDOX had the dual effect on antitumor activity and liver metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1443.

Ellagic acid nanoliposomes potentiate therapeutic effects of PEGylated liposomal doxorubicin in melanoma: An in vitro and in vivo study

Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines

Synergistic Effects of Antitumor Efficacy Via Mixed Nano-Size Micelles of Multifunctional Bletilla Striata Polysaccharide-Based Copolymer and D-α-tocopheryl Polyethylene Glycol Succinate.

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma

Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation

The study of the treatment of breast cancer by the combined photothermal therapy of Lycium barbarum polysaccharide doxorubicin gel

Effect of O-4-Ethoxyl-Butyl-Berbamine in Combination with Pegylated Liposomal Doxorubicin on Advanced Hepatoma in Mice

Nucleolin-targeted doxorubicin and ICG co-loaded theranostic lipopolymersome for photothermal-chemotherapy of melanoma in vitro and in vivo

Enhanced in vitro antitumor efficacy of a polyunsaturated fatty acid-conjugated pH-responsive self-assembled ion-pairing liposome-encapsulated prodrug

Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma

Targeted Delivery of a Combination Therapy Consisting of Combretastatin A4 and Low-Dose Doxorubicin Against Tumor Neovasculature.

Co-delivery of Doxorubicin Encapsulated PLGA Nanoparticles and Bcl-xL shRNA Using Alkyl-Modified PEI into Breast Cancer Cells

PEGylated phospholipid micelles containing D-α-tocopheryl succinate as multifunctional nanocarriers for enhancing the antitumor efficacy of doxorubicin

Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide

Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models

Abstract 1443: Dual effect of novel polyethyleneglycol modified liposome on antitumor activity and liver metastasis

Combination of Doxorubicin with Harmine-Loaded Liposomes Exerting Synergistic Antitumor Efficacy.

Enhanced antitumor efficacy and attenuated cardiotoxicity of doxorubicin in combination with lycopene liposomes

The Synergistic Inhibitory Effect of Combination Drug Treatment of Enteromorpha Prolifera Polysaccaharide and Doxorubicin Hydrochloride on A549 Cell